Abstract： Objective To explore the clinical efficacy and safety of ganshuang granules combined with tenofovir disoproxil fumarate tablets in the treatment of decompensated liver cirrhosis.Methods 70 patients with decompensated liver cirrhosis admitted to Ganzhou City Nankang District Hospital of Traditional Chinese Medicine from February 2020 to December 2022 were randomly divided into a study group and a control group,with 35 patients in each group.The control group was treated with tenofovir disoproxil fumarate tablets,while the study group was treated with ganshuang granules combined with tenofovir disoproxil fumarate tablets.Both groups were treated for 6 months.The clinical efficacy of the two groups was compared.The changes of liver function indicators[total bilirubin(TBIL),alanine aminotransferase(ALT),aspartate aminotransferase(AST)],liver fibrosis indicators[laminin(LN),hyaluronic acid(HA),type Ⅳcollagen(Ⅳ-C)]before and after treatment were compared between the two groups.At the same time,the occurrence of adverse reactions during drug use was compared between the two groups.Results After 6 months of treatment,the total effective rate of the study group was higher than that of the control group(P＜0.05);the elastic values of TBIL,ALT,AST,LN,HA,Ⅳ-C in both groups decreased,and the study group was lower than the control group(P＜0.05).The incidence of adverse reactions during the medication period between the two groups was compared,and the study group was lower than the control group(P＜0.05).Conclusion The combination of ganshuang granules and tenofovir disoproxil fumarate tablets in the treatment of decompensated liver cirrhosis can significantly improve clinical efficacy,improve the degree of liver fibrosis in patients,and have high safety.